Please use this identifier to cite or link to this item:
https://doi.org/10.1038/s41598-019-49155-4
DC Field | Value | |
---|---|---|
dc.title | MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression | |
dc.contributor.author | Nama, S. | |
dc.contributor.author | Muhuri, M. | |
dc.contributor.author | Di Pascale, F. | |
dc.contributor.author | Quah, S. | |
dc.contributor.author | Aswad, L. | |
dc.contributor.author | Fullwood, M. | |
dc.contributor.author | Sampath, P. | |
dc.date.accessioned | 2022-01-07T03:49:59Z | |
dc.date.available | 2022-01-07T03:49:59Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Nama, S., Muhuri, M., Di Pascale, F., Quah, S., Aswad, L., Fullwood, M., Sampath, P. (2019). MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression. Scientific Reports 9 (1) : 12718. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-019-49155-4 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/213243 | |
dc.description.abstract | Breast cancer manifests as a spectrum of subtypes with distinct molecular signatures, and different responses to treatment. Of these subtypes, triple-negative breast cancer (TNBC) has the worst prognoses and limited therapeutic options. Here we report aberrant expression of microRNA-138 (miR-138) in TNBC. Increased miR-138 expression is highly specific to this subtype, correlates with poor prognosis in patients, and is functionally relevant to cancer progression. Our findings establish miR-138 as a specific diagnostic and prognostic biomarker for TNBC. OncomiR-138 is pro-survival; sequence-specific miR-138 inhibition blocks proliferation, promotes apoptosis and inhibits tumour growth in-vivo. miR-138 directly targets a suite of pro-apoptotic and tumour suppressive genes, including tumour suppressor candidate 2 (TUSC2). miR-138 silences TUSC2 by binding to a unique 5?-UTR target-site, which overlaps with the translation start-site of the transcript. Over-expression of TUSC2 mimics the phenotype of miR-138 knockdown and functional rescue experiments confirm that TUSC2 is a direct downstream target of miR-138. Our report of miR-138 as an oncogenic driver in TNBC, positions it as a viable target for oligonucleotide therapeutics and we envision the potential value of using antimiR-138 as an adjuvant therapy to alleviate this therapeutically intractable cancer. © 2019, The Author(s). | |
dc.publisher | Nature Publishing Group | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Scopus OA2019 | |
dc.type | Article | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.contributor.department | BIOCHEMISTRY | |
dc.description.doi | 10.1038/s41598-019-49155-4 | |
dc.description.sourcetitle | Scientific Reports | |
dc.description.volume | 9 | |
dc.description.issue | 1 | |
dc.description.page | 12718 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1038_s41598-019-49155-4.pdf | 2.71 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License